Order Article Reprints

Butzkueven H, Giacomini PS, Cohan S, Ziemssen T, Sienkiewicz D, Zhang Y, Geissbühler Y, Silva D, Tomic D, Kropshofer H, et al. Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study. Brain Sciences. 2022; 12(2):215. https://doi.org/10.3390/brainsci12020215

Butzkueven, Helmut, Paul S. Giacomini, Stanley Cohan, Tjalf Ziemssen, Daniel Sienkiewicz, Ying Zhang, Yvonne Geissbühler, Diego Silva, Davorka Tomic, Harald Kropshofer, and et al. 2022. "Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study" Brain Sciences 12, no. 2: 215. https://doi.org/10.3390/brainsci12020215

Butzkueven, H., Giacomini, P. S., Cohan, S., Ziemssen, T., Sienkiewicz, D., Zhang, Y., Geissbühler, Y., Silva, D., Tomic, D., Kropshofer, H., & Trojano, M. (2022). Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study. Brain Sciences, 12(2), 215. https://doi.org/10.3390/brainsci12020215